Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

INTRODUCTION: Graft-versus host disease (GVHD) is a major limitation to the success of allogeneic hematopoietic cell transplant (HCT). We hypothesized that the GVHD prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac) and mycophenolate mofetil (MMF) would reduce the incid...

Descripción completa

Detalles Bibliográficos
Autores principales: El Jurdi, Najla, Hoover, Alex, O’Leary, Daniel, Cao, Qing, Gupta, Ashish, Ebens, Christen, Maakaron, Joseph, Betts, Brian C., Rashidi, Armin, Juckett, Mark, Lund, Troy, Bachanova, Veronika, MacMillan, Margaret, Miller, Jeffrey, Orchard, Paul, Wagner, John, Vercellotti, Gregory, Weisdorf, Daniel, Dusenbery, Kathryn, Terezakis, Stephanie, Holtan, Shernan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081397/
https://www.ncbi.nlm.nih.gov/pubmed/37034603
http://dx.doi.org/10.1101/2023.03.24.23287521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081397/
https://www.ncbi.nlm.nih.gov/pubmed/37034603
http://dx.doi.org/10.1101/2023.03.24.23287521

Ejemplares similares